Rheumatoid arthritis therapy with genetically engineered biological agents in the Republic of Karelia

The paper considers whether a current treatment option for rheumatoid arthritis with genetically engineered biological agents that selectively block the activity of individual proinflammatory mediators and cell surface antigens involved in autoimmune inflammation may be performed in Karelia, which c...

Full description

Bibliographic Details
Published in:Modern Rheumatology Journal
Main Author: Irina Mikhailovna Marusenko
Format: Article in Journal/Newspaper
Language:Russian
Published: IMA-PRESS LLC 2013
Subjects:
генно-инженерные биологические препараты
инфликсимаб
моноклональные антитела
ревматоидный артрит
ритуксимаб
фактор некроза опухоли α
Medicine
R
Republic of Karelia
Online Access:https://doi.org/10.14412/1996-7012-2013-2446
https://doaj.org/article/ffe47e33567e4b80842c0a3466d389b1
Description
Summary:The paper considers whether a current treatment option for rheumatoid arthritis with genetically engineered biological agents that selectively block the activity of individual proinflammatory mediators and cell surface antigens involved in autoimmune inflammation may be performed in Karelia, which can achieve control of the disease, retard its progression, and improve prognosis.

Similar Items